Global Microbiome Therapeutics 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI07251605

Publication Date:

July 2, 2025

Pages:

144

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Microbiome Therapeutics market size is predicted to grow from US$ 227 million in 2025 to US$ 1674 million in 2031; it is expected to grow at a CAGR of 39.5% from 2025 to 2031.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
麻豆原创 competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
The 鈥淢icrobiome Therapeutics Industry Forecast鈥� looks at past sales and reviews total world Microbiome Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Microbiome Therapeutics sales for 2025 through 2031. With Microbiome Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Microbiome Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Microbiome Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Microbiome Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Microbiome Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Microbiome Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Microbiome Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Microbiome Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Upper GIT
Lower GIT
Segmentation by Application:
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Microbiome Therapeutics 麻豆原创 Size (2020-2031)
2.1.2 Microbiome Therapeutics 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Microbiome Therapeutics by Country/Region (2020, 2024 & 2031)
2.2 Microbiome Therapeutics Segment by Type
2.2.1 Upper GIT
2.2.2 Lower GIT
2.3 Microbiome Therapeutics 麻豆原创 Size by Type
2.3.1 Microbiome Therapeutics 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Microbiome Therapeutics 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Microbiome Therapeutics Segment by Application
2.4.1 C. difficile Infection (CDI)
2.4.2 Inflammatory Bowel Disease (IBD)
2.4.3 Orphan Drug
2.4.4 Immuno-oncology
2.4.5 Others
2.5 Microbiome Therapeutics 麻豆原创 Size by Application
2.5.1 Microbiome Therapeutics 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Microbiome Therapeutics 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Microbiome Therapeutics 麻豆原创 Size by Player
3.1 Microbiome Therapeutics 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Microbiome Therapeutics Revenue by Player (2020-2025)
3.1.2 Global Microbiome Therapeutics Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Microbiome Therapeutics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Microbiome Therapeutics by Region
4.1 Microbiome Therapeutics 麻豆原创 Size by Region (2020-2025)
4.2 Global Microbiome Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Microbiome Therapeutics 麻豆原创 Size Growth (2020-2025)
4.4 APAC Microbiome Therapeutics 麻豆原创 Size Growth (2020-2025)
4.5 Europe Microbiome Therapeutics 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Microbiome Therapeutics 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Microbiome Therapeutics 麻豆原创 Size by Country (2020-2025)
5.2 Americas Microbiome Therapeutics 麻豆原创 Size by Type (2020-2025)
5.3 Americas Microbiome Therapeutics 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Microbiome Therapeutics 麻豆原创 Size by Region (2020-2025)
6.2 APAC Microbiome Therapeutics 麻豆原创 Size by Type (2020-2025)
6.3 APAC Microbiome Therapeutics 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Microbiome Therapeutics 麻豆原创 Size by Country (2020-2025)
7.2 Europe Microbiome Therapeutics 麻豆原创 Size by Type (2020-2025)
7.3 Europe Microbiome Therapeutics 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Microbiome Therapeutics by Region (2020-2025)
8.2 Middle East & Africa Microbiome Therapeutics 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Microbiome Therapeutics 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Microbiome Therapeutics 麻豆原创 Forecast
10.1 Global Microbiome Therapeutics Forecast by Region (2026-2031)
10.1.1 Global Microbiome Therapeutics Forecast by Region (2026-2031)
10.1.2 Americas Microbiome Therapeutics Forecast
10.1.3 APAC Microbiome Therapeutics Forecast
10.1.4 Europe Microbiome Therapeutics Forecast
10.1.5 Middle East & Africa Microbiome Therapeutics Forecast
10.2 Americas Microbiome Therapeutics Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Microbiome Therapeutics Forecast
10.2.2 Canada 麻豆原创 Microbiome Therapeutics Forecast
10.2.3 Mexico 麻豆原创 Microbiome Therapeutics Forecast
10.2.4 Brazil 麻豆原创 Microbiome Therapeutics Forecast
10.3 APAC Microbiome Therapeutics Forecast by Region (2026-2031)
10.3.1 China Microbiome Therapeutics 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Microbiome Therapeutics Forecast
10.3.3 Korea 麻豆原创 Microbiome Therapeutics Forecast
10.3.4 Southeast Asia 麻豆原创 Microbiome Therapeutics Forecast
10.3.5 India 麻豆原创 Microbiome Therapeutics Forecast
10.3.6 Australia 麻豆原创 Microbiome Therapeutics Forecast
10.4 Europe Microbiome Therapeutics Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Microbiome Therapeutics Forecast
10.4.2 France 麻豆原创 Microbiome Therapeutics Forecast
10.4.3 UK 麻豆原创 Microbiome Therapeutics Forecast
10.4.4 Italy 麻豆原创 Microbiome Therapeutics Forecast
10.4.5 Russia 麻豆原创 Microbiome Therapeutics Forecast
10.5 Middle East & Africa Microbiome Therapeutics Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Microbiome Therapeutics Forecast
10.5.2 South Africa 麻豆原创 Microbiome Therapeutics Forecast
10.5.3 Israel 麻豆原创 Microbiome Therapeutics Forecast
10.5.4 Turkey 麻豆原创 Microbiome Therapeutics Forecast
10.6 Global Microbiome Therapeutics Forecast by Type (2026-2031)
10.7 Global Microbiome Therapeutics Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Microbiome Therapeutics Forecast
11 Key Players Analysis
11.1 Seres Therapeutics
11.1.1 Seres Therapeutics Company Information
11.1.2 Seres Therapeutics Microbiome Therapeutics Product Offered
11.1.3 Seres Therapeutics Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Seres Therapeutics Main Business Overview
11.1.5 Seres Therapeutics Latest Developments
11.2 Assembly Biosciences
11.2.1 Assembly Biosciences Company Information
11.2.2 Assembly Biosciences Microbiome Therapeutics Product Offered
11.2.3 Assembly Biosciences Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Assembly Biosciences Main Business Overview
11.2.5 Assembly Biosciences Latest Developments
11.3 Synthetic Biologics
11.3.1 Synthetic Biologics Company Information
11.3.2 Synthetic Biologics Microbiome Therapeutics Product Offered
11.3.3 Synthetic Biologics Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Synthetic Biologics Main Business Overview
11.3.5 Synthetic Biologics Latest Developments
11.4 Interxon
11.4.1 Interxon Company Information
11.4.2 Interxon Microbiome Therapeutics Product Offered
11.4.3 Interxon Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Interxon Main Business Overview
11.4.5 Interxon Latest Developments
11.5 PureTech
11.5.1 PureTech Company Information
11.5.2 PureTech Microbiome Therapeutics Product Offered
11.5.3 PureTech Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 PureTech Main Business Overview
11.5.5 PureTech Latest Developments
11.6 Synlogic
11.6.1 Synlogic Company Information
11.6.2 Synlogic Microbiome Therapeutics Product Offered
11.6.3 Synlogic Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Synlogic Main Business Overview
11.6.5 Synlogic Latest Developments
11.7 Enterome BioScience
11.7.1 Enterome BioScience Company Information
11.7.2 Enterome BioScience Microbiome Therapeutics Product Offered
11.7.3 Enterome BioScience Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Enterome BioScience Main Business Overview
11.7.5 Enterome BioScience Latest Developments
11.8 4D Pharma
11.8.1 4D Pharma Company Information
11.8.2 4D Pharma Microbiome Therapeutics Product Offered
11.8.3 4D Pharma Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 4D Pharma Main Business Overview
11.8.5 4D Pharma Latest Developments
11.9 Second Genome
11.9.1 Second Genome Company Information
11.9.2 Second Genome Microbiome Therapeutics Product Offered
11.9.3 Second Genome Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Second Genome Main Business Overview
11.9.5 Second Genome Latest Developments
11.10 AOBiome
11.10.1 AOBiome Company Information
11.10.2 AOBiome Microbiome Therapeutics Product Offered
11.10.3 AOBiome Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 AOBiome Main Business Overview
11.10.5 AOBiome Latest Developments
11.11 C3 Jian
11.11.1 C3 Jian Company Information
11.11.2 C3 Jian Microbiome Therapeutics Product Offered
11.11.3 C3 Jian Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 C3 Jian Main Business Overview
11.11.5 C3 Jian Latest Developments
11.12 Rebiotix
11.12.1 Rebiotix Company Information
11.12.2 Rebiotix Microbiome Therapeutics Product Offered
11.12.3 Rebiotix Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Rebiotix Main Business Overview
11.12.5 Rebiotix Latest Developments
11.13 MicroBiome Therapeutics LLC
11.13.1 MicroBiome Therapeutics LLC Company Information
11.13.2 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Offered
11.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 MicroBiome Therapeutics LLC Main Business Overview
11.13.5 MicroBiome Therapeutics LLC Latest Developments
11.14 Metabiomics
11.14.1 Metabiomics Company Information
11.14.2 Metabiomics Microbiome Therapeutics Product Offered
11.14.3 Metabiomics Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Metabiomics Main Business Overview
11.14.5 Metabiomics Latest Developments
11.15 Ritter Pharmaceuticals
11.15.1 Ritter Pharmaceuticals Company Information
11.15.2 Ritter Pharmaceuticals Microbiome Therapeutics Product Offered
11.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Ritter Pharmaceuticals Main Business Overview
11.15.5 Ritter Pharmaceuticals Latest Developments
11.16 Symberix
11.16.1 Symberix Company Information
11.16.2 Symberix Microbiome Therapeutics Product Offered
11.16.3 Symberix Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Symberix Main Business Overview
11.16.5 Symberix Latest Developments
11.17 OpenBiome
11.17.1 OpenBiome Company Information
11.17.2 OpenBiome Microbiome Therapeutics Product Offered
11.17.3 OpenBiome Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 OpenBiome Main Business Overview
11.17.5 OpenBiome Latest Developments
11.18 Azitra
11.18.1 Azitra Company Information
11.18.2 Azitra Microbiome Therapeutics Product Offered
11.18.3 Azitra Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Azitra Main Business Overview
11.18.5 Azitra Latest Developments
11.19 Symbiotix Biotherapies
11.19.1 Symbiotix Biotherapies Company Information
11.19.2 Symbiotix Biotherapies Microbiome Therapeutics Product Offered
11.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Symbiotix Biotherapies Main Business Overview
11.19.5 Symbiotix Biotherapies Latest Developments
11.20 Osel
11.20.1 Osel Company Information
11.20.2 Osel Microbiome Therapeutics Product Offered
11.20.3 Osel Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Osel Main Business Overview
11.20.5 Osel Latest Developments
11.21 Metabogen
11.21.1 Metabogen Company Information
11.21.2 Metabogen Microbiome Therapeutics Product Offered
11.21.3 Metabogen Microbiome Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.21.4 Metabogen Main Business Overview
11.21.5 Metabogen Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.